Medicine and Dentistry
Valganciclovir
100%
Placebo
100%
Epstein Barr Virus
90%
Donor
90%
Cytomegalovirus
60%
Prophylaxis
30%
Virus Infection
30%
Therapeutic Procedure
30%
Transplantation
20%
Virus Replication
20%
Viremia
20%
Posttransplant Lymphoproliferative Disease
20%
Side Effect
20%
Morbidity
10%
Diseases
10%
Leukopenia
10%
Cytomegalovirus Infection
10%
Virus Strain
10%
Organ Donor
10%
Virus Transmission
10%
Survival Time
10%
Virus DNA
10%
Latent Membrane Protein 1
10%
Epstein-Barr Virus Infection
10%
Mortality
10%
Kidney
10%
Incidence
10%
Biopsy
10%
Pharmacology, Toxicology and Pharmaceutical Science
Valganciclovir
100%
Epstein-Barr Virus
90%
Cytomegalovirus
60%
Virus Infection
30%
Viremia
20%
Posttransplant Lymphoproliferative Disease
20%
Diseases
10%
Leukopenia
10%
Morbidity
10%
Virus DNA
10%
Virus Strain
10%
Survival Time
10%
Cytomegalovirus Infection
10%
Mortality
10%
Epstein Barr Virus Infection
10%
Virus Transmission
10%
Incidence
10%
Virus
10%
Epstein-Barr Virus Latent Membrane Protein 1
10%
Immunology and Microbiology
Epstein Barr Virus
100%
Cytomegalovirus
70%
Transplantation
20%
Viremia
20%
Viral Replication
20%
Lymphoproliferative Disorders
20%
Viral Disease
20%
Morbidity
10%
Membrane
10%
Virus Strain
10%
Survival Time
10%
Virus Transmission
10%
DNA Virus
10%
Lymphoid Tissue
10%
Mortality
10%
Organ
10%
Kidney
10%
Incidence
10%
Virus
10%
INIS
epstein-barr virus
100%
diseases
30%
prophylaxis
30%
transmission
20%
tissues
10%
range
10%
organs
10%
transplants
10%
dna
10%
strains
10%
origin
10%
administration
10%
kidneys
10%
variations
10%
mortality
10%
biopsy
10%
morbidity
10%
side effects
10%
viruses
10%
peaks
10%
membrane proteins
10%
survival time
10%
viral diseases
10%
leukopenia
10%